Edoxaban is the first oral anticoagulant on the market in Japan, and it is also the first time in the world. This product can inhibit thrombosis through selective, reversible and direct inhibition of FXa. Its good tolerance, oral absorption and anticoagulant activity have been verified by clinical development.
According to the classification of the World Health Organization (WHO), antibacteriological agents for systemic use are usually divided into 8 subclasses, namely, cefazoles, penicillins, macrolids and linkers, aminoglycosides, quinolones, carbapenems, nitroimidazoles and other anti-infective agents.
Behind the prosperity of China's API industry, there are many challenges, which make its development encounter difficulties.Objectively speaking, China is currently the world leader in API, and the market is still expanding.